INTRODUCTION
============

Digestive enzymes are produced and secreted by the gastrointestinal system to degrade fats, proteins, and carbohydrates, to accomplish the digestion and, afterwards, the absorption of nutrients. Their supplementation, when indicated, may provide a reliable help as an adjuvant treatment of several disorders characterized by an impairment of digestive functions. To date, various formulations of enzyme supplementation are available on the market, and they are currently used in clinical practice for the management of several digestive diseases, especially those involving organs designated to the production of digestive enzymes, including the exocrine pancreas (which produces pancreatic enzymes) and the small intestinal brush border (which produces lactase).

Pancreatic enzyme supplementation is the therapy of choice for the management of exocrine pancreatic insufficiency (EPI) in chronic pancreatitis, pancreatic cancer, cystic fibrosis (CF) or diabetes \[[@R1]-[@R6]\].

Another relevant application of enzyme supplementation in the clinical practice is the management of lactose intolerance. It is estimated that 75 percent of individuals worldwide experience hypolactasia, or some decrease of lactase activity, especially during adulthood \[[@R7]\].

Recent evidence suggests that digestive enzymes may be useful also in celiac disease, but they are far from being used in the routine management of the disease. In celiac disease a lifelong gluten-free diet may bring about difficulties as avoiding gluten completely is problematic owing to the contamination with gluten of presumably gluten free foods \[[@R8]\]. New therapeutic approaches include enzyme supplementation, correction of the intestinal barrier defect against gluten entry, blocking of gliadin presentation by human leukocyte antigen blockers and tissue transglutaminase inhibitors \[[@R9]\].

Finally, conjugated bile acids, even if are not classifiable as enzymes, are able to promote absorption of dietary lipids by emulsifying them in micelles, so we included them in this review.

This paper will provide an overview of the current knowledge of digestive enzyme supplementation in gastrointestinal diseases and include also publications with animals and *in vitro* studies. We did a non-systematic but thorough review of the available literature. Respectively, indications, biochemical features and dosages of pancreatic enzymes, lactase (β-galactosidase), conjugated bile acids and endopeptidases will be reviewed. Finally, our hypothesis for a possible scenario of digestive enzyme supplementation in the next future will be presented.

PANCREATIC ENZYME SUPPLEMENTATION
=================================

Indications
-----------

EPI is a life-threatening condition associated to several pancreatic and extra-pancreatic diseases (chronic pancreatitis, acute pancreatitis, cystic fibrosis, pancreatic cancer, Schwachman syndrome and as a consequence of gastrointestinal and pancreatic surgery). Patients with EPI who lose weight, those with daily fecal fat excretion higher than 15 g under a diet including 100 g fat per day, and those with relevant steatorrhea-related symptoms are classically considered as requiring enzyme substitution therapy \[[@R5]\].

Furthermore, pancreatic enzyme supplementation could be used to relief abdominal pain in chronic pancreatitis, since the introduction of exogenous enzymes is supposed to play a negative feedback regulation on endogenous enzyme secretion, with consequent reduction of pancreatic duct pressure. Notwithstanding, their use in clinical practice remains controversial \[[@R1]\] and different studies are looking for criteria predicting a clinical response in this subset of patients \[[@R2]\].

Enzyme Features
---------------

Pancreatic enzymes can be divided into three groups, according to their respective function: proteolytic enzymes (mainly trypsinogen and chymotripsinogen and their active forms trypsin and chymotripsin), amylolitic enzymes (pancreatic amylase), and lipolitic enzymes (principally lipase) \[[@R10]\].

Exogenous pancreatic enzymes are primarily extracted from porcine or bovine sources. Lipase may also be synthesized from microbial sources, such as Aspergillus oryzae and Rhizopus arrhizus \[[@R11]\].

As described in animal studies, advantages of microbe-derived enzymes are the requirement of a lower dosage to be effective and a broader pH range of activity than animal-based counterparts \[[@R12]\]; however, porcine pancreatin, which contains trypsin, amylase and lipase, is actually the only pancreatic enzyme replacement therapy (PERT) available in the UK \[[@R13]\].

Commercially available formulations are both non-enteric-coated and enteric-coated: this latter preparation has been developed to facilitate the passage of ingested enzymes through the hostile acid milieu of the stomach and duodenum, because the efficacy of exogenous enzyme supplementation is decreased by low pH; lipase is indeed irreversibly denatured when exposed to pH ≤4 13, 14\].

Until April 2010, pancreatic replacement therapy did not require safety and efficacy data to be submitted to FDA. Since April 2010, FDA required clinical trials and Investigational New Drug Application submission for the approval of pancreatic enzymes preparations in the United States, thus leading to the removal of previously available products from the market \[[@R3]\]. Six products have obtained FDA approval in US: Creon and Zenpep (2009) Pancreaze (2010), Ultresa, Viokace and Pertzye (2002) \[[@R15]\].

Liprotamase is a novel biotechnology-derived, non-porcine enzyme replacement therapy containing three purified and stable enzymes: cross-linked crystalline lipase, crystalline protease and amorphous amylase. Since the stability (resistance against proteolysis and stability at acid pH) is an intrinsic characteristic of the individual enzyme, coating is not required. In a phase III trial, a dose of one capsule per meal (5 capsules per day) was well tolerated, increased fat and protein absorption and significantly decreased stool weight in patients with cystic fibrosis \[[@R4]\].

Recommended Dosages and Daily Posology for the Formulation
----------------------------------------------------------

The required daily dose of pancreatin is variable, being related to the etiology and severity of pancreatic insufficiency and clinical features of the patient, such as age and body weight, and, for cystic fibrosis, also genotype and intestinal factors affecting absorption. Preparations of pancreatic enzyme are dosed by lipase content. However, many evidences suggest that a minimal dose of 25 000--50 000 U of lipase per meal is generally required to reduce steatorrhoea to \<15 g fat per day in adults \[[@R16]-[@R18]\]. When dealing with cystic fibrosis, 500--3000 U lipase ⁄ kg per meal are recommended, and \<6000 or 10 000 U lipase ⁄ kg ⁄ day in children. Children aged \>4 years tend to eat less fat per kilogram than at ages \<4 years requiring fewer enzyme dosage (500 vs. 1000 U lipase ⁄ kg ⁄ meal respectively) \[[@R19]\].

Enzymatic Activity and Relevance of Enzymes Contained in the Formulation
------------------------------------------------------------------------

The activity and concentration of these enzymes are determined by multiple factors, including animal's species, age and sex, as well as husbandry practices. Pancreatic physiology of hogs is more similar to humans than any other animal species. Enzymatic activity levels from pork sources are approximately 30- to 50-percent higher than beef sources \[[@R5]\].

However, commercially available formulations differ from each other in terms of enzyme (lipase, amylase, protease) content. In Table **[1](#T1){ref-type="table"}**, a non-comprehensive list of exogenous pancreatic enzyme formulations available to date in Europe is shown (Table **[1](#T1){ref-type="table"}**, adapted from MIMS \[[@R6]\]).

Table **[2](#T2){ref-type="table"}** compares enzymatic activity of pancreatic and fungal-based enzymes \[[@R5]\].

LACTASE (β-GALACTOSIDASE) SUPPLEMENTATION
=========================================

Indications
-----------

Lactase deficiency represents the main cause of lactose malabsorption. Lactase is an enzyme produced by intestinal villi, which is able to hydrolyze lactose into galactose and glucose. High lactase concentrations are normally present in neonates, but, after weaning, its activity decrease in most people in a genetically-based fashion, driving to the so-called primary lactose malabsorption. Secondary hypolactasia, instead, can result from any damage of the small intestinal mucosal brush border or increase of the gastrointestinal transit time. Lactose intolerance is defined when lactose malabsorption causes gastrointestinal symptoms \[[@R20]\].

Even if, strong evidences suggest usefulness of lactase supplementation in lactose intolerance, also in infants, this issue is not covered by available guidelines.

Enzyme Features
---------------

Replacement of native lactase through the use of exogenous enzymes, derived from yeast or fungi, with microbial exogenous lactase (obtained from yeasts or fungi) may be considered a reliable therapeutic option. Exogenous lactase can be administered with milk, or as capsules/tablets before eating dairy products. The latter formulations are widely available on the market, and several studies have investigated and confirmed their efficacy \[[@R21]-[@R24]\].

Enzymatic Activity and Recommended Dosages
------------------------------------------

At the same dose, enzymes obtained from different microorganisms display different efficacy in hydrolyzing lactose. Comparative studies showed that lactase derived from K. lactis displays higher efficacy than lactase from A. niger \[[@R25], [@R26]\]. Enzymatic activity depends on features of commercial formulations. Table **[3](#T3){ref-type="table"}** shows some common lactase brands, widely used in US and Europe, with each own enzymatic activity.

Moreover, in a study from Lin *et al*, three different lactase formulations (Lactogest -soft gel capsule, Lactaid --caplet-, and DairyEase -chewable tablet-), compared with placebo, were fed to lactose intolerants with either 20 g or 50 g of lactose; the trial was performed with 6000 IU (respectively four capsules of Lactogest - two caplets of Lactaid or two tablets of DairyEase) and 3000 IU (two capsules of Lactogest) of lactase. All enzyme preparations were able to decrease the peak as well as total breath H2, when a 20g-dosage of lactose was administered. 6000 IU of lactase treatment reduced total hydrogen production significantly (P \< 0.05) below that observed with 3000 IU dosage. Symptoms improved significantly (P \< 0.05) with all the products. When a dosage of 50 g of lactose was administered, neither 3000 nor 6000 IU of beta-gal were able to improve the digestion and absorption of lactose. Results from these studies demonstrate the relative equivalency of chewable, caplet, and soft-gel beta-gal products, based on IUs of enzyme fed \[[@R27]\].

CONJUGATED BILE ACIDS
=====================

Indications and Features
------------------------

Conjugated bile acids are amphipathic molecules that emulsify the lipolysis product of dietary triglycerides and fat-soluble vitamins. In particular, ursodeoxycholic acid (UDCA) is a tertiary bile acid widely used in the treatment of different cholestatic diseases \[[@R28]\]. Several Cochrane reviews evaluated beneficial and harmful effects of UDCA in patients with non-alcoholic fatty liver disease/steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, after liver transplant \[[@R29]-[@R32]\]. Nevertheless, none of them lead out a significant evidence to support or refuse the use of bile acids in such diseases, often because of the small sample size of the studies reviewed, except in the case of primary biliary cirrhosis where a benefit on survival was excluded \[[@R30]\]. Furthermore, a meta-analysis by Manley and colleagues showed that UDCA can prevent gallstone formation in patient undergone to bariatric surgery \[[@R33]\]. Bile acids have been evidenced to be useful also in progressive familial intrahepatic cholestatis (PFIC), with a decrease of cholestasis and hepatocytonecrosis markers, and an improvement of hepatic functional test, with a dose of 20-30 mg/kg/day, over a period ranging from 2 to 4 years \[[@R34]\].

Recommended Dosages and Daily Posology for the Formulation
----------------------------------------------------------

In prolonged use, the mean daily posology is about 5-10 mg/Kg, or rather 300-600 mg/die in the majority of cases, in the treatment of biliary lytiasis. To treat dyspepsia, 300 mg/die, divided in 2-3 administrations, are considered an effective dosage.

In the retard formulation, daily posology is 450 mg/die, but in obese patients, or in presence of important risk factors for lithiasis, it is beneficial to raise dose to 675 mg/die. In dyspepsia, a smaller dose (225 mg/die) is recommended \[[@R34]\].

ENZYME SUPPLEMENTATION IN CELIAC DISEASE
========================================

Celiac disease (CD) is a multifactorial disease featured by an inflammatory response to ingested gluten in the small intestine; gluten peptides rich in proline and glutamine (from wheat, barley, rye), elicit an immune reaction in genetically predisposed subjects. Actually, gluten-free diet is the only accepted treatment for celiac disease \[[@R35]\].

Prolyl endopeptidases (PEPs) are a group of serine proteases that break down proline remnants in peptides \[[@R36], [@R37]\]. Recently PEPs have been evaluated as a possible therapy for celiac disease, because of their capacity for enhance the degradation of gluten peptides in the gut, as shown through both *in vitro* and *in vivo* studies, emphasizing also the hypothesis of a combination enzyme therapy (endopeptidase plus another protease) \[[@R8], [@R36]-[@R38]\].

Even if these reports are promising, actually there is not yet a role for PEPs for the treatment of CD, neither commercial preparations are available. Further and larger studies are needed to confirm these interesting results.

RATIONAL DESIGN OF AN ENZYME COMBINATION THERAPY
================================================

As seen in this review, each exogenous enzyme plays a relevant role in the treatment of digestive disorders. Such evidence theoretically suggest that a "super-enzyme", containing digestive enzymes (except those still being tested and not available for clinical practice, such as prolyl endopeptidase), may be of interest in a selected number of conditions, such as severe pancreatic insufficiency other causes of severe malabsorption syndrome, conditions of severe malnutrition, "fragile" patients, such as the great elderly or infants. This hypothetic formulation should contain, for each enzyme, at least its lower dosage when used alone. Other interesting associations come out from several evidences of pathophysiology of digestive enzymes: in patients with pancreatic insufficiency the bicarbonate secretion, necessary for neutralizing the duodenal acid chyme, could be severely impaired, forbidding the correct working of exogenous pancreatic enzymes, so that addition of PPI is actually recommended in refractory steatorrhea. Following this evidence, a formulation including a PPI in association with pancreatin may be useful in some cases of severe pancreatic failure.

Moreover, according to Gass *et al*, conjugated bile acids, not only promote lipid absorbtion, but could also accelerate the hydrolysis of dietary proteins by pancreatic proteases, so that a possible association should be useful in pancreatic disorders, especially in biliary etiology \[[@R39], [@R40]\]. In addition, UDCA plays a role in liver disease of cystic fibrosis, improving biochemical markers of cholestasis, nutritional/general status and histologic pattern: a unique preparation including UDCA plus pancreatin may be of interest in cystic fibrosis with liver involvement.

Finally, the impairment of gut microbiota can worsen or cause alterations of digestive functions, so the restoration of the microbial homeostasis represents a reliable therapeutic option for the management of several digestive disorders \[[@R41]\].

The presence of bacterial overgrowth in human EPI has been studied using non-invasive breath tests or by duodenal juice sampling and culture \[[@R42]-[@R47]\]. These studies have shown that small intestinal bacterial overgrowth can complicate from a quarter to a half of cases of EPI, suggesting that it might contribute to development or persistence of diarrhea in patients with EPI and adequate pancreatic enzyme supplementation \[[@R44], [@R47]-[@R49]\].

Moreover, bacterial overgrowth is often observed, in experimental models of EPI, but also in dogs with naturally occurring pancreatic failure \[[@R50], [@R51]\].

In addition, in a pig model of pancreatic insufficiency -- with a previous clonation of the Staphylococcus hyicus lip gene in Lactococcus lactis - the coefficient of fat absorption was higher after consumption of lipase-expressing L. lactis than that after consumption of the inactive control strain \[[@R52]\].

Furthermore, fermented milk derivatives are able to increase the absorption of lactose, and to reduce the symptoms of intolerance in patients with lactose malabsorption, since yogurt microbes display an intrinsic lactase activity. Yogurt derives from the incubation of milk together with two lactic acid bacteria, *Lactobacillus bulgaricus* and *Streptococcus thermophiles,* which play an active role in the hydrolysis of lactose during the fermentation (which reduces the content of dietary lactose by 25-50%) as well as after the consumption of lactose \[[@R53]-[@R57]\].

So, according to these data, a probiotic addition, respectively to lactase in the treatment of lactose intolerance, and to pancreatic enzymes in the treatment of pancreatic insufficiency, may constitute a new, intriguing, convenient formulation in the therapy of these diseases, but always providing a tailored choose of the probiotic strain to be used \[[@R58]\].

The combination of digestive enzymes and probiotics may be an interesting option also in the field of CD: *Aspergillus niger*, which produces one of the endopeptidases studied for this aim (AN-PEP), has been studied also for the use of another product called aspergillopepsin, which is not specific for gluten epitopes. This protein, in conjunction with dipeptidyl-peptidase IV, can have a role in degrading larger proteins into smaller fragments, exposing the residues to more specific endopeptidases or exopeptidases \[[@R59], [@R60]\].

Nevertheless, further studies are needed to support this hypothesis.

CONCLUSION
==========

As reviewed in this paper, enzyme supplementation therapy may play an important role in several digestive and malabsorption disorders, such as EPI and lactose intolerance. Currently, the animal-derived enzymes represent an established standard of care, however the growing study of plant-based and microbe-derived enzymes offers great promise in the advancement of digestive enzyme therapy.

New frontiers of enzyme replacement are being evaluated also in the treatment of diseases not specifically related to enzyme deficiency, such as CD, whereas the combination of different enzymes might constitute an intriguing therapeutic option in the future. Furthermore, a tailored probiotic addition to the enzyme supplement, for example to lactase in the treatment of lactose intolerance, and to pancreatic enzymes in the treatment of pancreatic insufficiency, seems to offer an advantage to the therapeutic management of such disorders.
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###### 

List of exogenous pancreatic enzyme formulations available in Europe.

  ----------------------------------------------------------------------------------------------------
  **Trade Name**                            **Lipase (U)**     **Amylase (U)**     **Protease (U)**
  ----------------------------------------- ------------------ ------------------- -------------------
  Non-enteric coated                                                               

  Pancrex V powder\                         25000              30000               1400
  (100/250/300g)                                                                   

  Pancrex granules                          5000               4000                300

  Pancrex V capsules                        8000               9000                430

  Pancrex V tablets                         1900               1700                110

  Enteric coated                                                                   

  Creon 10                                  10 000             8000                600

  Creon 25                                  25 000             18 000              1000

  Creon Micro                               5000               3600                200

  Nutrizym 10                               10 000             9000                500

  Nutrizym 22                               22000              19800               1100

  Pancrease HL                              25000              22500               1200

  Pancrex V Forte tablets                   56000              5000                330

  Enteric coated \[porcine derived\]:                                              

  Pertzye                                   8,000 USP units    30,250 USP units    28,750 USP units

  Pertzye                                   16,000 USP units   60,500 USP units    57,500 USP units

  Enteric coated \[porcine derived\]:                                              

  Pancrelipase (Lip-Prot-Amyl)              5000 USP units     27,000 USP units    17,000 USP units

  Zenpep                                    3000 USP units     16,000 USP units    10,000 USP units

  Zenpep                                    5000 USP units     27,000 USP units    17,000 USP units

  Zenpep                                    10,000 USP units   55,000 USP units    34,000 USP units

  Zenpep                                    15,000 USP units   82,000 USP units    51,000 USP units

  Zenpep                                    20,000 USP units   109,000 USP units   68,000 USP units

  Zenpep                                    25,000 USP units   136,000 USP units   85,000 USP units

  Cotazym                                   10,000 USP units   40,000 USP units    35,000 USP units

  Cotazym                                   10,800 USP units   42,000 USP units    45,000 USP units

  Cotazym                                   25,000 USP units   100,000 USP units   100,000 USP units

  Enteric coated \[porcine derived\]:                                              

  Creon                                     3000 USP units     15,000 USP units    9500 USP units

  Creon                                     6000 USP units     30,000 USP units    19,000 USP units

  Creon                                     12,000 USP units   60,000 USP units    38,000 USP units

  Creon                                     24,000 USP units   120,000 USP units   76,000 USP units

  Creon                                     36,000 USP units   180,000 USP units   114,000 USP units

  Lipram                                    10,000 USP units   30,000 USP units    30,000 USP units

  Lipram                                    16,000 USP units   48,000 USP units    48,000 USP units

  Lipram                                    18,000 USP units   58,500 USP units    58,500 USP units

  Lipram                                    16,000 USP units   48,000 USP units    48,000 USP units

  Lipram                                    20,000 USP units   65,000 USP units    65,000 USP units

  coated \[porcine derived\]:                                                      

  Pancreaze                                 4200 USP units     17,500 USP units    10,000 USP units

  Pancreaze                                 10,500 USP units   43,750 USP units    25,000 USP units

  Pancreaze                                 16,800 USP units   70,000 USP units    40,000 USP units

  Pancreaze                                 21,000 USP units   61,000 USP units    37,000 USP units

  Pangrol                                   10,000 Ph.Eur.U    9,000 Ph.Eur.U      500 Ph.Eur.U

  Pangrol                                   20,000 Ph.Eur.U    12,000 Ph.Eur.U     900 Ph.Eur.U

  Pangrol                                   25,000 Ph.Eur.U    22,500 Ph.Eur.U     1,250 Ph.Eur.U

  Panzytrat                                 25,000 Ph.Eur.U    22,000 Ph.Eur.U     1,250 Ph.Eur.U

  Ozym                                      40,000 Ph.Eur.U    25,000 Ph.Eur.U     1,500 Ph.Eur.U

  Enteric coated \[porcine derived\]:                                              

  Ultresa                                   13,800 USP units   27,600 USP units    27,600 USP units

  Ultresa                                   20,700 USP units   41,400 USP units    41,400 USP units

  Ultresa                                   23,000 USP units   46,000 USP units    46,000 USP units

  Non-enteric coated \[porcine derived\]:                                          

  Viokace                                   10,440 USP units   39,150 USP units    46,000 USP units

  Viokace                                   20,880 USP units   78,300 USP units    78,300 USP units
  ----------------------------------------------------------------------------------------------------

###### 

Comparison between pancreatic and fungal-based enzymatic activity. SKB: Sandstedt, Keen and Blish, Cereal Chemistry 12, 172, 1939, based on the digestion of starch over time.

  **Enzyme**       **Pancreatin**   **Microbe-derived**
  ---------------- ---------------- ------------------------
  Amylase units    ≈89 USP          100 SKB (4800 USP)\*
  Protease units   ≈197 USP         500 HUT (3250 USP)\*\*
  Lipase units     ≈80 USP          100 LU\*\*\*

HUT: Hemoglobin Units; based on enzymatic hydrolysis of denatured hemoglobin. LU: Lipase Units; based on lipolytic activity utilizing olive oil. USP: U.S. Pharmacopoeia units. \*1 SKB=48 USP;\*\*1 HUT = approximately 6.5 USP; \*\*\* No conversion available to USP

###### 

Common lactase brands, widely used in US and Europe, with each own enzymatic activity.

  **Trade Name**   **Lactase (U)**
  ---------------- -----------------
  Silact           \>30.000
  Lacdigest        2250
  Lactaid          9000
  Digerlat         100000
  Dairy-Ease       3000
